scholarly journals Development and Characterization of Nanobodies Targeting the Kupffer Cell

2021 ◽  
Vol 12 ◽  
Author(s):  
Fang Zheng ◽  
Jinhong Zhou ◽  
Zhenlin Ouyang ◽  
Jiaxin Zhang ◽  
Xinyi Wang ◽  
...  

Nanobodies that are derived from single-chain antibodies of camelids have served as powerful tools in diagnostics, therapeutics and investigation of membrane receptors' structure and function. In this study, we developed a series of nanobodies by a phage display screening building from lymphocytes isolated from an alpaca immunized with recombinant mouse Kupffer cell receptor Clec4F, which is involved in pathogen recognition by binding to galactose and N-acetylgalactosamine. Bio-panning selections retrieved 14 different nanobodies against Clec4F with an affinity ranging from 0.2 to 2 nM as determined by SPR. Those nanobodies mainly recognize 4 different epitopes as analyzed via competitive epitope binning. By analysis of the radioactivity in each organ after injection of 99mTc labeled Clec4F nanobodies in naïve mice, we found that these nanobodies are targeting the liver. Furthermore, we performed a structural characterization at atomic resolution of two of the Clec4F nanobodies from different epitope groups, which revealed distinct features within the CDR2 and CDR3 regions. Taken together, we developed a series of nanobodies targeting multiple distinct recognition epitopes of the Kupffer cell-specific receptor Clec4F which may be useful for its structural and functional investigation as well as for use as molecular imaging and therapeutic agents.

2010 ◽  
Vol 137 (3-4) ◽  
pp. 251-260 ◽  
Author(s):  
Sy-Jye Leu ◽  
Yu-Ching Lee ◽  
Neng-Yao Shih ◽  
I-Jen Huang ◽  
Ko-Jiunn Liu ◽  
...  

2009 ◽  
Vol 101 (06) ◽  
pp. 1012-1019 ◽  
Author(s):  
Constantin von zur Muhlen ◽  
Dominik von Elverfeldt ◽  
Karlheinz Peter ◽  
Christoph Hagemeyer

SummaryOver three decades after the generation of the first mouse monoclonal antibodies by Kohler and Milstein, recombinant antibodies are the fastest growing class of therapeutic proteins. Furthermore, antibodies are key detection reagents in research and diagnostics. Technology improvements have provided several approaches to manufacturing human antibodies with high affinity for biologically relevant targets. Approximately 300 development programs for therapeutic antibodies have been reported in industrial and academic laboratories, and this clearly demonstrates the expectations towards antibody technology. Antibody fragments are a subclass with growing clinical importance. This review focuses on single-chain antibodies as one of the smallest possible format for recombinant antibodies and their use as diagnostic tools and therapeutic agents. We describe the structure, selection and production of single-chain antibodies. Furthermore, we review current applications of antibody fragments focusing on thrombus targeting using fibrin- and platelet-specific single-chain antibodies as well as describing novel noninvasive imaging approaches for the diagnosis of thrombosis and inflammation.


PLoS ONE ◽  
2017 ◽  
Vol 12 (1) ◽  
pp. e0170162 ◽  
Author(s):  
Amy M. Hurwitz ◽  
Wanzhi Huang ◽  
Baijun Kou ◽  
Mary K. Estes ◽  
Robert L. Atmar ◽  
...  

1992 ◽  
Vol 89 (10) ◽  
pp. 4759-4763 ◽  
Author(s):  
W. F. Hoo ◽  
M. J. Lacy ◽  
L. K. Denzin ◽  
E. W. Voss ◽  
K. D. Hardman ◽  
...  

Biochemistry ◽  
1996 ◽  
Vol 35 (40) ◽  
pp. 13212-13221 ◽  
Author(s):  
Hidetaka Kosako ◽  
Yoshiko Akamatsu ◽  
Naoya Tsurushita ◽  
Kyung-Kwon Lee ◽  
Yukiko Gotoh ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document